Antinuclear antibodies and elevated anti-Epstein-Barr virus titers in cancer patients.

One and one-half percent of human sera from patients seen at a clinic for treatment of cancer contained antibodies to the nuclei of chick kidney cells by indirect immunofluorescence tests. In the group of sera containing antinuclear antibodies, the geometric mean titer to Epstein-Barr virus (EBV) capsid antigen was significantly elevated. Sera obtained from normal adults or from patients with similar histological types of tumors that possessed no antinuclear antibodies contained lower levels of anti-EBV antibodies. The elevated titers to EBV were correlated with the presence or absence of antinuclear antibodies and not with a particular type or site of neoplastic disease.     

Intrathecal synthesis of virus antibodies in multiple sclerosis patients.

A follow-up study on the intrathecal synthesis of viral antibodies in multiple sclerosis patients was made on 28 patients over a period of about 2 years. Serial serum and cerebrospinal fluid specimens were assayed for antibodies against measles, rubella, parainfluenza type 2, respiratory syncytial, mumps, influenza A, influenza B, adeno, and herpes simplex viruses by employing a solid-phase enzyme immunoassay technique. All patients had local antibody synthesis against one or more of the antigens studied. Rubella and measles virus antibodies were found with the highest frequency and were synthesized at the highest rate. Simultaneous intrathecal antibody synthesis against the greater number of the viruses studied was associated with higher local immunoglobulin G synthesis. A good overall correspondence in the fluctuations of the different viral antibodies synthesized intrathecally was usually found. Sometimes the changes in intrathecal antibody levels correlated well with the changes in immunoglobulin G index and sometimes not. These fluctuations could not be correlated with the clinical course of the disease. The results of this study suggest that the viral antibodies studied are not relevant to the etiology or the pathogenesis of multiple sclerosis.     

Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis

In order to investigate the possible involvement of viruses in Multiple Sclerosis (MS), the study evaluated the presence of viral genomic sequences in cerebrospinal fluid (CSF), as markers of viral replication within the central nervous system (CNS). A total of 85 CSF samples were collected from 38 MS patients, 28 patients with other neurological diseases and 19 subjects without neurological diseases. Using nested-PCR, the investigation focused on the presence of human herpes virus DNA, including herpes simplex virus 1 (HSV-1) and 2 (HSV-2), the Epstein-Barr virus (EBV), varicella zoster virus (VZV), human cytomegalovirus (HCMV), human herpes virus 6 (HHV-6) and JC virus (JCV). All the CSF samples from the individuals without neurological diseases were negative for viral DNA. Genomic sequences of HSV-1, HCMV, EBV, HHV6, and JCV were found in patients with MS and other neurological diseases without significant differences between the two groups. VZV DNA was detected more frequently (P < 0.05) in the MS group (31.6%), particularly among the relapsing-remitting MS patients (43.5%), compared with patients with other neurological diseases (10.7%). In addition, the results indicated that JCV and HHV-6 were replicating actively in the CNS of a small, but significant number of patients with MS and other neurological diseases. Most importantly, the study revealed a high frequency of VZV DNA in the CSF of patients with MS, suggesting a possible role of this virus in the pathogenesis of MS.     

Proteasome antibodies in patients with cancer or multiple sclerosis

Proteasome antibodies were detected by enzyme-linked immunosorbent assay in two of the 45 (4.4%) patients with lung cancer, 0 of the 39 patients with breast cancer and six of the 51 (11.8%) patients with ovarian cancer. Six of the 47 (12.8%) patients with relapsing remitting multiple sclerosis had proteasome antibodies, as well as two of the 100 (2%) blood donors. Significant higher odds ratios compared to the blood donors were found for the patients with ovarian cancer (OR: 6.4; 95% CI: 1.1–68) and multiple sclerosis (OR: 7.1; 95% CI: 1.2–74). There was no association between proteasome antibodies and metastases or onconeural antibodies. The antibodies showed reactivity to 23, 25 and 27 kD proteins of the 20S proteasome using Western blot. The increased prevalence of proteasome antibodies in patients with ovarian cancer or multiple sclerosis may reflect cellular damage and release of intracellular antigens. Whether the antibodies take part in the clearance of released proteasomes and thus participate in the pathogenesis of cancer or autoimmune disease is not known.     

血清EB病毒抗体水平与鼻咽癌患者预后的关系

目的 探讨血清EB病毒VCA/IgA、EA/IgA、NA1/IgA及Rta/IgG抗体水平与鼻咽癌患者预后的关系.方法 140例初治无远处转移的鼻咽癌患者分别在治疗前和治疗结束后采用免疫酶法检测血清VCA/IgA和EA/IgA,ELISA法检测NA1/IgA和Rta/IgG.随访进行远期疗效和生存的评价.结果 治疗后患者血清VCA/IgA、EA/IgA、NA1/IgA及Rta/IgG抗体水平较治疗前有明显下降,但仍显著高于正常对照组(P＜0.05).治疗后持续缓解的鼻咽癌患者其治疗前VCA/IgA、EA/IgA抗体水平显著低于疾病进展患者(P＜0.05).血清VCA/IgA、EA/IgA、NA1/IgA及Rta/IgG抗体水平与患者的3年总生存率无关(P＞0.05).治疗前VCA/IgA抗体高水平组(≥1∶320)及EA/IgA抗体高水平组(≥1∶80)患者的无进展生存期(61.8％,61.3％)低于抗体低水平组患者(86.5％,86.5％;P＜0.001).Cox回归分析显示治疗前VCA/IgA抗体水平是影响无进展生存的独立危险因素(HR=3.80,P=0.001).结论 VCA/IgA、EA/IgA可为鼻咽癌患者预后判断提供帮助.     

Immunoglobulin G subclass antibodies to measles virus in patients with subacute sclerosing panencephalitis or multiple sclerosis

Mouse monoclonal antibodies specific for human immunoglobulin G (IgG) subclasses and a sensitive immunoassay were used to evaluate the IgG subclass antibody response to measles virus antigens in cerebrospinal fluid and serum samples from 20 patients with subacute sclerosing panencephalitis (SSPE), 12 patients with multiple sclerosis (MS), and 11 controls with high measles virus antibody titers in serum. In patients with SSPE, measles virus-specific antibodies were found mainly in the IgG1 subclass and the IgG subclass distribution remained unchanged, irrespective of the clinical stage or duration of the disease. In patients with MS and in controls, measles virus activity was also associated mainly with IgG1. However, the activity was significantly lower than that found in patients with SSPE. The results suggest that there is no primary abnormality in humoral immune response to measles virus in patients with MS. The disproportionately high levels of the measles virus-specific IgG1 subclass found in patients with SSPE may be due to persistent antigenic stimulation or reflect a defect in immunoregulatory mechanisms in response to viral infection.     

Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis

An increased frequency of antiviral CD8+ T cells is seen in chronic viral infections. During herpes virus infections the expanded CD8+ T cells are thought to control the reactivation of the latent infection. Because multiple sclerosis (MS), a presumed autoimmune disease of the central nervous system, has been associated with a late Epstein-Barr virus (EBV) infection, we wished to examine whether the CD8+ T cell response to EBV epitopes differed between MS patients and healthy controls. Here we report an increased frequency of CD8+ T cells responding to EBV epitopes from nuclear antigen 3 A (HLA-A2/CLG) and latent membrane protein 2 (HLA-B7/RPP) in MS patients. Noticeably, the altered CD8+ T cell response occurred to some but not all EBV epitopes and did not reach the high level seen during acute infection. The responses towards two immunodominant epitopes from human cytomegalovirus (HCMV) were similar in MS patients and normal controls. Together, our data demonstrate the presence of an increased frequency of CD8+ T cells reacting with two epitopes from EBV in patients with MS. The altered response to only two of the tested EBV epitopes would be consistent with the presence of cross-reactive epitopes.     

Amylolytic activity of IgM and IgG antibodies from patients with multiple sclerosis

IgG and IgM antibodies from the sera of patients with multiple sclerosis (MS) were found to possess amylolytic activity hydrolyzing alpha-(1-->4)-glucosyl linkages of maltooligosaccharides, glycogen, and several artificial substrates. Individual IgM fractions isolated from 54 analyzed patients with the clinically definite diagnoses of MS had approximately three orders of magnitude higher specific amylolytic activity than that for healthy donors, whereas IgG from only a few patients had high amylolytic activity. Strict criteria were used to prove that the amylolytic activity of IgMs and IgGs is their intrinsic property and is not due to any enzyme contamination. Fab fragments produced from IgM and IgG fractions of the MS patients displayed the same amylolytic activity. IgMs from various patients demonstrated different modes of action in hydrolyzing maltooligosaccharides.     

Cytotoxic antibodies in multiple sclerosis

Serum cold cytotoxic activities against allocells: total lymphocytes, B lymphocytes and monocytes were detected in 12 of 21 multiple sclerosis (MS) patients at 15 degrees C using a microcytotoxicity technique. Cytotoxic activity was found at 37 degrees C in certain MS patients. This activity was weak or absent in non MS patients and in healthy controls. Tests with autocells were positive in 6 MS patients. Cerebrospinal fluid cytotoxic activity was found in MS as well as in non-MS diseases; at 37 degrees C CSF produced lysis of monocytes in the absence of complement. No correlation was found between cytotoxic activity and parameters of clinical disease. Our results suggest that there may be a wide variety of cytotoxic antibodies in MS. Their significance is unknown; it may be that they have an effect on certain lymphocyte subsets as it has been suggested in other diseases.     

Treatment of multiple sclerosis with anti-CD20 antibodies

The recently successful targeting of B cells in patients with multiple sclerosis (MS) using monoclonal antibodies (mAbs) targeting CD20 has established that it is no longer a question of whether B cells contribute, but how they contribute, to MS disease activity. Here, the focus will be to review results that have emerged over the last few years from clinical trials of different anti-CD20 mAbs in patients with MS. We will also consider the biological basis underlying the apparent therapeutic efficacy of B cell depletion in MS. To this end, we will draw on several instructive observations made in MS patients who were treated with the anti-CD20 mAb rituximab. While the initial application of rituximab to patients with MS was based on the concept that B cell depletion may translate into decreases in potentially pathogenic CNS-autoreactive antibodies, insights from these studies have underscored the importance of non-antibody mediated functions of B cells.     

Monoclonal antibodies in treatment of multiple sclerosis

Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti‐alpha4‐integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing–remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing–remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.     

Altered collagen expression in jugular veins in multiple sclerosis

IntroductionVenous abnormalities have been associated with different neurological conditions, and the presence of a vascular involvement in multiple sclerosis (MS) has long been anticipated. In view of the recent debate regarding the existence of cerebral venous outflow impairment in MS due to abnormalities of the azygos or internal jugular veins (IJVs), we have studied the morphological and biological features of IJVs in MS patients.MethodsWe examined (a) IJVs specimens from MS patients who underwent surgical reconstruction of the IJV and specimens of the great saphenous vein used for surgical reconstruction, (b) different vein specimens from an MS patient dead of an unrelated cause, and (c) autoptical and surgical IJV specimens from patients without MS. Collagen deposition was assessed by means of Sirius red staining followed by polarized light examination. The expression of collagen type I and III, cytoskeletal proteins (α-smooth muscle actin and smooth muscle myosin heavy chains), and inflammatory markers (CD3 and CD68) was investigated.ResultsThe extracranial veins of MS patients showed focal thickenings of the wall characterized by a prevailing yellow–green birefringence (corresponding to thin, loosely packed collagen fibers) correlated to a higher expression of type III collagen. No differences in cytoskeletal protein and inflammatory marker expression were observed.DiscussionThe IJVs of MS patients presenting a focal thickening of the vein wall are characterized by the prevalence of loosely packed type III collagen fibers in the adventitia. Further studies are required to determine whether the observed venous alterations play a role in MS pathogenesis.     

Age-related reactivity of lymphocytes from multiple sclerosis patients to myelin basic protein

Peripheral blood lymphocytes from 51 multiple sclerosis (MS) patients and 23 healthy individuals were examined for their response to human myelin basic protein at three concentrations. Cells from active-MS patients responded in most cases with definitely enhanced blastogenic stimulation (BS), whereas those of the nonactive-MS patients or of patients in remission showed values of BS similar to or below those of the control group. Patients and control individuals were divided in two groups according to their age. The younger group included individuals from 20 to 40 years of age, the older those from 41 to 68 years. The lowest and highest values obtained using the three doses of basic protein was selected and the results compared. The higher values of BS and the greater frequency of active blood samples were observed in the younger than in the older active-MS patients. On the other hand, a larger number of samples obtained from the older patients showed the lowest values of BS. The relevance of age to the suppressor activity induced by the basic protein in the lymphocytes of MS patients is discussed.     

Regulation of disease susceptibility: Decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis

The development of restricted cytokine profiles by subsets of CD4⁺ T cells is a pivotal point in the regulation of immune responses. T cells producing Th1 cytokines (IL-2 and interferon-γ) induce cell-mediated immunity, whereas T cells producing Th2 cytokines (IL-4, IL-5, and IL-10) play a prominent role in the induction of humoral immunity. We examined a group of patients with multiple sclerosis, a disease caused by excess production of Th1 cytokines in myelin-reactive T cells, and control patients with noninflammatory neuroconvulsive disorders, for the presence of allergic disease, which is caused by excess production of Th2 cytokines in allergen-specific T cells. The patients with multiple sclerosis had significantly fewer allergic symptoms, a lower number of positive allergen-specific IgE test results, and lower composite allergy indexes than control subjects. These results demonstrate that the prevalence of IgE-mediated allergic disease is decreased in a group of patients with multiple sclerosis and support the hypothesis that genetic factors that promote susceptibility to Th1-mediated inflammatory disease in human beings protect against the development of Th2-mediated disease. (J ALLERGY CLIN IMMUNOL 1996;97:1402-8.)